SOM Biotech granted orphan drug designation by the FDA for SOM3355


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Latest FDA approval news

SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SOM3355, currently in clinical development for the treatment of chorea movements in Huntington´s Disease (HD).

The FDA Office of Orphan Products Development grants orphan status to support the development of drugs for the safe and effective treatment of rare disorders. Receiving ODD may qualify SOM Biotech for a seven year period of US marketing exclusivity upon approval of SOM3355.

Raúl Insa, Chief Executive Officer of SOM Biotech highlights: “Receiving Orphan Drug Designation for SOM3355 is a significant step forward for Huntington’s Disease patients and confirms the potential of our AI-powered approach to accelerate drug discovery and development. SOM3355’s profile is a compelling alternative to existing drugs in this space and we are excited by the added momentum that Orphan Drug Designation gives to the project to ensure we can make this treatment available as soon as possible to patients.”

HD is an inherited disorder whereby progressive degeneration of brain centers involved in movement can result in chorea, an involuntary, jerky, movement that randomly affects somatic muscles and flows from one part of the body to another. Using the Company’s proprietary artificial intelligence-based computational technology (SOMAI PRO), SOM Biotech identified SOM3355 or Bevantolol hydrochloride, a drug commonly used to treat hypertension, as a vesicular monoamine transporter 2 (VMAT2) inhibitor that could be repositioned to treat chorea in HD but with a much better side-effect profile than the current standard-of-care.

Tags : #SomBiotech #FDANews #Som3355

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026